Cell transplant promises treatment of Alzheimer's

[Guest guest]

Cell transplant promises treatment of Alzheimer's

By Mark , Science Correspondent

TRANSPLANTS of genetically engineered skin cells can slow the progress

of Alzheimer's disease, the first human trial of its kind has revealed.

The new therapy, which involves injecting the modified tissue deep into

patients' brains, increased neural activity and substantially reduced

the rate of mental decline, scientists report today.

Although the results come from a preliminary safety trial of only eight

patients and need to be repeated on a much larger scale, they are seen

as hugely promising by researchers.

There is no effective treatment for Alzheimer's and the research offers

the first proof of the principle that cell transplants have the

potential to help people with the degenerative brain condition. " If

validated in further clinical trials, this would represent a

substantially more effective therapy than current treatments for

Alzheimer's disease, " Mark Tuszynski, a Professor of Neurosciences at

the University of California in San Diego, who led the study, said.

" This would also represent the first therapy for a human neurological

disease that acts by preventing cell death. "

He pointed out, however, that the study was designed to test only the

safety and not the efficacy of the technique -- thus the experiment had

no control group receiving placebo treatment against which its value

could be judged. A placebo-controlled double-blind trial is under way at

Rush University Medical Centre in Chicago and its results will be a more

accurate measure of therapeutic potential.

In the research, which began in 2001, Professor Tuszynski's team took

skin cells from eight patients in whom the early stages of Alzheimer's

had been diagnosed. These cells were then genetically modified to make a

protein called nerve growth factor (NGF), which prevents nerve death and

stimulates activity.

Extensive previous research has shown that transplants of cells that

express NGF restored atrophied brain cells in aged monkeys and that the

technique is also effective on mice.

The eight patients who took part in the trial were awake but under light

sedation during the operation. Two of the patients moved as the cells

were being injected but the six patients who completed the surgery

without any ill-effects all appeared to benefit from their treatment.

Injections in the full clinical trial will be performed under general

anaesthesia.

The results are published today in the journal Nature Neuroscience.

" When administered into the central nervous system . . . [NGF] treatment

is well tolerated and had the potential to improve symptoms and modify

neurological disease progression, " Professor Tuszynski said.

Print this article

Send to a friend

http://www.timesonline.co.uk/_nipd/emailAFriend.php?id=3-1\

584211','emailFriend1584211','dependent=yes,resizable=no,scrollbars=no,height=40\

0,width=520');>

Back to top of page

http://www.timesonline.co.uk/article/0,,3-1584211,00.html#>